| Document |
Document Title |
|
WO/2019/173582A1 |
In alternative embodiments, provided are processes comprising the continuous isolation and purification of cannabinoids and further isomerization of the purified cannabidiol to Δ8tetrahydrocannabinol ( Δ8THC) and Δ9tetrahydrocannabino...
|
|
WO/2019/172699A1 |
The present specification provides a compound represented by chemical formula 1 and an organic light emitting device comprising same.
|
|
WO/2019/168198A1 |
[Problem] To provide a non-fluorescent rhodamine dye which forms a TICT state. [Solution] A compound represented by general formula (I) or a salt thereof.
|
|
WO/2019/168972A1 |
Disclosed are methods for preparing a salt of urolithin A and, in turn, urolithin A. The methods are advantageous for the large-scale preparation of urolithin A or a pharmaceutically acceptable salt thereof.
|
|
WO/2019/169001A1 |
The present invention provides compounds that modulate the interaction of TCR with Nck, compositions thereof, and methods of treatment using the same.
|
|
WO/2019/168199A1 |
[Problem] To provide a fluorescent probe which includes, as the base nucleus, a fluorescent skeleton functioning in the visible light region and which makes carboxypeptidase activity visible with high sensitivity. [Solution] A compound r...
|
|
WO/2019/161509A1 |
An apparatus and method is provided for producing kief from cannabis plants. The apparatus includes a drum that rotates about a horizontal axis that cannabis plants are placed inside. As the drum rotates, kief separates from the cannabis...
|
|
WO/2019/164914A1 |
The present inventions relates to compounds and compositions and their applications as pharmaceuticals for ameliorating injury to, or weakness of, or loss of, bone, or to prevent bone fractures. Exemplified herein is the administration t...
|
|
WO/2019/164689A1 |
A method of increasing the cannabinoid levels in a genetically modified Cannabis sativa plant includes genetically modifying the plant to induce the overexpression of the gene that controls the expression of tetrahydrocannabinolic acid (...
|
|
WO/2019/158505A1 |
A method of extracting at least one cannabinoid from a biomass comprises the following steps: (i) contacting the biomass with a solvent formulation which comprises a C1-4 fluorinated hydrocarbon or a C1-4 hydrofluorocarbon ether, thereby...
|
|
WO/2019/157592A1 |
A process of producing an edible powder containing cannabis including providing a desired quantity of cannabis oil, a cannabis isolate or a cannabis distillate, mixing the cannabis oil, cannabis isolate or cannabis distillate with a solv...
|
|
WO/2019/158514A1 |
Disclosed is a process for the oxidation of at least one chroman (C1) in a solvent mixture comprising at least two solvents or in a C-bearing solvent, with a gaseous compound comprising, essentially consisting of, or consisting of oxygen...
|
|
WO/2019/159168A1 |
The present invention provides cannabinoid derivatives, more specifically cannabidiol (CBD), desoxy-CBD, and desoxy-A9- tetrahydrocannabinol (desoxy-THC) derivatives, which are useful for neuroprotection, treating pain, or treating a dis...
|
|
WO/2018/140738A8 |
Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, which are activators of nuclear factor erythroid 2 (NF-E2) -related factor 2 (Nrf2) and are useful to treat diseases caused by oxidative stress, such as n...
|
|
WO/2019/153088A1 |
A composition for oral administration comprising a cannabinoid in combination with a stilbenoid or derivative thereof and a solubility enhancing agent is described. Oral dosage forms, in the form of dissolvable tablet or capsule with enh...
|
|
WO/2019/149091A1 |
The present invention relates to the field of compounds, and in particular to a probucol derivative, a preparation method therefor and use thereof, the probucol derivative having a structure represented by general formula I. The probucol...
|
|
WO/2019/144221A1 |
Compositions for treating bedsores and methods for treating bedsores are provided. The compositions include a therapeutically effective amount of nabilone and may be formulated for oral or topical administration. The composition may furt...
|
|
WO/2019/145552A1 |
The present specification discloses methods of purifying one or more cannabinoids from a plant material using unique biphasic solvent systems and liquid-liquid chromatography as centrifugation partitioning chromatography (CPC) or counter...
|
|
WO/2019/141229A1 |
The present invention involves compounds as PPAR agonists and applications thereof. The compounds involved are novel peroxisome proliferator-activated receptor (PPAR) γ receptor agonists and can inhibit the production of mitochondrial r...
|
|
WO/2019/129909A1 |
The present invention describes compounds of formula I comprising a central prenylated benzopyran structure. Said compounds of formula I, stereoisomers and pharmaceutically acceptable salts thereof exhibit activity as PPARα, PPARγ agon...
|
|
WO/2019/128175A1 |
Disclosed are a cocrystal of tocopherol and proline and a preparation method therefor. The cocrystal is in crystalline or partially crystalline form in the environment of normal pressure and room temperature. Compared to the existing toc...
|
|
WO/2019/126872A1 |
The disclosure relates to solid formulations comprising decarboxylated cannabis resin. The disclosure provides rapidly disintegrating sublingual tablet formulations comprising decarboxylated cannabis resin, and methods for making and usi...
|
|
WO/2019/119141A1 |
The present application is directed to compounds of Formula (I): compounds of Formula (II): compounds of Formula (III): and compounds of Formula (IV): compositions comprising these compounds and their uses, for example as medicaments and...
|
|
WO/2019/120210A1 |
The present invention discloses benzofuran and Coumestans derivatives represented by the formulas (I), (II), (III), (IV), a preparation method thereof, and a use of the benzofurans and Coumestans derivative compounds in the treatment of ...
|
|
WO/2019/126144A1 |
Described herein are polymeric fluorophores that include a dye, a polymer, and optionally a bioconjugate group. A polymeric fluorophore may have a structure represented by: A-B-C or C-A-B, wherein A is a dye; B is a polymer comprising on...
|
|
WO/2019/126778A1 |
The present disclosure provides isolated nepetalactone oxidoreductase polypeptides (NORs), nepetalactol synthases (NEPSs), and related polynucleotides, engineered host cells, and cultures, as well as methods for producing NORs and NEPSs,...
|
|
WO/2019/120099A1 |
The present invention relates to an organic mixture and the use thereof in an organic electronic device. The organic mixture comprises organic materials H1 and H2, wherein H1 is a compound as shown in the following general formula (1), a...
|
|
WO/2019/116177A1 |
The present invention relates to novel 3-ketocoumarins with improved water compatibility, which are useful as photoinitiators and to compositions comprising said photoinitiators. The invention also relates to compositions comprising said...
|
|
WO/2019/113693A1 |
Compounds that are inhibitors of retinoic acid inducible P450 (CYP26) enzymes. The compounds have retinoid activity, are resistant to CYP26-mediated catabolism, act as inhibitors of CYP26B1, and are used for treating diseases that are re...
|
|
WO/2019/116176A1 |
The present invention relates to a series of novel polymerizable compounds based on 3-ketocoumarins, which are useful as photoinitiators and sensitizers, to compositions comprising said compounds and to a process for photopolymerizing co...
|
|
WO/2019/099750A9 |
Provided herein are compositions, methods, systems and/or kits for preventing and/or treating neoplasms using at least one modulator selected from quercetin, sodium phenyl butyrate and epigallocatechin-3-gallate in combination with one o...
|
|
WO/2019/114501A1 |
The present invention provides an α-mangostin derivative having a structure of general formula I, a preparation method thereof, and an application of the same in preparing a drug for treating a brain injury caused by ischemia, such as v...
|
|
WO/2019/113861A1 |
A ginkgo biloba extract medicinal raw material and a preparation method therefor, the ginkgo biloba extract medicinal raw material comprising a mixture formed by compounding a general lactone purification product and a general flavonoid ...
|
|
WO/2019/111265A1 |
The present invention relates to novel compounds, compositions and methods of preparation thereof, as well as uses thereof for treating cancer of various types, including: pancreatic, liver, breast, colon, brain and lung cancer.
|
|
WO/2019/112143A1 |
Provided are a novel heterocyclic compound and an organic light emitting device using the same.
|
|
WO/2019/111093A1 |
The present invention relates to an improved process for the separation of gallated epicatechins (EGCG & ECG) from green tea extract or green tea dust. The present invention specifically relates to an improved process for the separation ...
|
|
WO/2019/069297A3 |
Activity-based probes that can be used to selectively identify and characterize enzymes that are involved in different phases of xenobiotic metabolism in a host and its microbiota population(s) are described. The activity-based probes de...
|
|
WO/2019/113602A1 |
A quaternary ammonium salt comprising a chromophore constituent, a tertiary amine cation constituent connected to the para-position of the chromophore constituent via a methylene linkage, and a borate anion constituent, wherein chromopho...
|
|
WO/2018/125880A8 |
Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.
|
|
WO/2019/105216A1 |
Disclosed is an epigallocatechin gallate crystal form I, wherein the X-ray powder diffractogram thereof has diffraction peaks at the following 2-Theta° positions: 8.5±1, 12.2±1, 15.6±1, 17.1±1, 20.8±1, 21.6±1, 24.6±1, and 25.9±1...
|
|
WO/2019/106238A1 |
The present disclosure relates to an improved process for the preparation of isochroman structured alpha2A adrenoceptor agonist, namely 2-(5-methoxyisochroman-1-yl)-4,5- dihydro-1H-imidazole of formula (I) and a pharmaceutically acceptab...
|
|
WO/2019/104442A1 |
Cannabis and cannabis derived formulations, methods of making and methods of using the formulation in oral dosage forms, preferably in beverage forms, are disclosed herein.
|
|
WO/2019/108877A1 |
Isoorientin analogues and related compounds that inhibit glycogen synthase kinase-3β activity are provided as are methods of using these compounds in the treatment of cognitive, neurodegenerative or neurological diseases or conditions, ...
|
|
WO/2019/101353A1 |
The invention relates to a method for directly producing morin derivatives and high-purity morin of formula (1). The invention also relates to morin derivatives and high-purity morin that can be obtained using the claimed method.
|
|
WO/2019/101826A1 |
The invention relates to amide-derivatives of 2-hydroxy-2-methyl-4-(3,5,6-trimethyl-1,4- benzoquinon-2-yl)-butanoic acid for use in a treatment for preventing or suppressing symptoms mediated by enhanced mPGES-1 expression or activity. I...
|
|
WO/2019/099750A1 |
Provided herein are compositions, methods, systems and/or kits for preventing and/or treating neoplasms using at least one modulator selected from quercetin, sodium phenyl butyrate and epigallocatechin-3-gallate in combination with one o...
|
|
WO/2019/090421A1 |
Described are methods for determining a recommended dosage and/or variety of cannabis for a subject based on genetic testing. The presence or absence of genetic variants in a sample from the subject is determined and used to determine a ...
|
|
WO/2019/093623A1 |
The present invention provides a novel heterocyclic compound and an organic light-emitting diode using the same.
|
|
WO/2019/094788A1 |
The present technology relates to compounds that inhibit human Ly6K and homologs thereof. Also disclosed are methods of using such compounds to: inhibit activity of a Ly6K protein in a cell; decrease migration, colony formation, and/or p...
|
|
WO/2019/090428A1 |
Refrigerated solvent is fed through a cooling jacket around an essential element extraction vessel. After circulating through the cooling jacket, the solvent is re-chilled and at least some of the solvent is passed into the extraction ve...
|
